GSK Shares Dive as Weaker Vaccine Sales Unnerve Investors

GSK shares fell sharply on Wednesday, making the British pharmaceutical company one of the biggest fallers on the FTSE 100, after weaker vaccine sales unsettled investors despite better than expected financial results. The decline underscores how closely the market is watching the company's vaccine franchise, which has become a central pillar of its growth story.

The sell-off came even as GSK's overall financial performance beat expectations, a combination that left investors focused on the softness in vaccine revenue rather than the headline numbers. Shares in the company dropped to rank among the weakest performers in London's blue-chip index, reflecting the weight investors place on the vaccines business.

The reaction highlights the sensitivity of GSK's valuation to its vaccine portfolio, where sales trends are scrutinised as a gauge of future growth. A weaker showing in that division can overshadow stronger results elsewhere in the business, as Wednesday's trading demonstrated.

For investors, the session served as a reminder that GSK's share price remains tightly linked to vaccine demand and the pace of sales in that segment. The company's ability to reinvigorate vaccine revenue is likely to remain a key focus for shareholders weighing the stock against its peers in the sector.

GSK's fall stood out on a day when the broader FTSE 100 backdrop did not shield the stock, with the company ranking among the index's largest decliners. The gap between better than expected results and the negative share price reaction illustrates how much of GSK's investment case now rests on the trajectory of its vaccines business.